Navigation Links
Funxional Successfully Completes Initial Clinical Trial of FX125L, an Anti-Inflammatory Drug With a Novel Mechanism of Action
Date:7/8/2009

CAMBRIDGE, England, July 8 /PRNewswire/ -- Funxional Therapeutics Ltd (Funxional) has announced today the successful completion of the first Phase I study with FX125L, an orally available small molecule which belongs to a new therapeutic class named Broad Spectrum Chemokine Inhibitors (BSCIs).

The Phase I, single ascending dose study was conducted in the United States. FX125L was well tolerated at all doses studied and no serious adverse events or subject withdrawals were observed. The pharmacokinetics of FX125L was linear over the wide dose range studied and consistent with once-daily oral dosing for patients.

"We are extremely pleased with the outcome of this initial clinical study with FX125L," said Konstantinos Efthymiopoulos, CEO of Funxional Therapeutics. "The results in humans are consistent with the preclinical data, suggesting that FX125L has a very wide safety margin, and confirmed the excellent drug-like profile of FX125L."

About Funxional Therapeutics Ltd.

Funxional Therapeutics is a privately held, clinical stage pharmaceutical company based in Cambridge (UK) which focuses on novel anti-inflammatory therapies. FXT is managed by a very experienced team and is financed by Index Ventures and Novo A/S, while its shareholders also include Ipsen and Cambridge University. FXT has research and office facilities in Cambridge.

For more information about FXT, please visit our web site (http://www.funxionaltherapeutics.com) or contact us by e-mail (info@funxionaltherapeutics.com).

About BSCIs

BSCIs are anti-inflammatory compounds with an entirely novel mechanism of action that involves the selective interaction with a well-characterized receptor, resulting in a potent inhibition of inflammatory cell migration. The compounds are anticipated to have broad applicability in inflammatory diseases.

BSCIs are one of the three proprietary technology platforms in FXT's portfolio all of which originated in the University of Cambridge. BSCIs were discovered based upon a strategy that exploits functional screening to develop novel new classes of drugs. FX125L is the lead drug candidate in this novel class, while other BSCIs have been identified as back up molecules or as candidates for development as topical anti-inflammatory agents.

For enquiries regarding this press release, please contact Konstantinos Efthymiopoulos, CEO of Funxional Therapeutics, at +44-1223-451095.


'/>"/>
SOURCE Funxional Therapeutics Limited
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Symphony Medical Announces First Patient Successfully Treated With Novel Congestive Heart Failure Therapy
2. Zenobia Therapeutics Successfully Completes Initial Phase of Its Service Agreement With Syntonix Pharmaceuticals
3. EnWave Successfully Commercializes nutraREV(TM) Food Dehydration Technology
4. Endo Pharmaceuticals Successfully Completes Tender Offer for Shares of Indevus Pharmaceuticals and Announces Subsequent Offering Period
5. WaferGens SmartChip(TM) System Performance Successfully Demonstrated in Initial Phase of Alpha Testing Program
6. GlaxoSmithKline Successfully Completes Tender Offer for Shares of Genelabs Technologies, Inc.
7. Shire Successfully Settles Former TKT Shareholder Appraisal Rights Litigation
8. Neptune Technologies successfully completes $2.75 million private placement with 10% management participation
9. Neptune Technologies successfully completes up to $8.5 million debt financing with Desjardins Group
10. SAFC Hitech(TM) Successfully Demonstrates Device-Quality GST Precursors For Phase Change Memory Applications
11. CoreValve Successfully Treats the First Pacific Rim Patients with Its ReValving System for Percutaneous Aortic Valve Replacement : Australia/New Zealand Regulatory-Cleared Evaluation Registry is Expected to Lead to Market Clearance for These Countries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... ... April 28, 2016 , ... As part ... top industry experts, and expanding its LATAM network and logistics capabilities. Enhancements ... to manage their clinical trial projects. , The expansion will provide unmatched clinical ...
(Date:4/27/2016)... ... 2016 , ... Shimadzu Scientific Instruments (SSI) will be showcasing ... Conference and Expo. Shimadzu’s high-performance instruments enable laboratories to test cannabis products for ... stop by booth 1021 to learn how Shimadzu’s instruments can help improve QA/QC ...
(Date:4/27/2016)... , April 27, 2016 ... (CSE: NSK) (OTCPink: NSKQB) ( Frankfurt ... an ihre Pressemitteilung vom 13. August 2015 die ... ihre Finanzen um zusätzliche 200.000.000 Einheiten auf 400.000.000 ... Dollar zu bringen. Davon wurden 157.900.000 Einheiten mit ...
(Date:4/27/2016)... ... April 27, 2016 , ... NDA Partners ... the company as an Expert Consultant. Mr. Clark was formerly a Vice ... the development of small molecule monographs based on analytical methods. NDA Partners ...
Breaking Biology Technology:
(Date:4/26/2016)... and LONDON , ... Finacle, part of EdgeVerve Systems, a product subsidiary ... Onegini today announced a partnership to integrate the ...      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) ... provide their customers enhanced security to access and ...
(Date:4/19/2016)... April 20, 2016 The new ... a compact web-based "all-in-one" system solution for all door ... reader or the door interface with integration authorization management ... control systems. The minimal dimensions of the access control ... the building installations offer considerable freedom of design with ...
(Date:4/15/2016)... , April 15, 2016 ... the,  "Global Gait Biometrics Market 2016-2020,"  report to ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,The global gait biometrics ... of 13.98% during the period 2016-2020. ... angles, which can be used to compute factors ...
Breaking Biology News(10 mins):